(Q36957806)

17 August 2017

1 reference

title

Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome (English)

1 reference

17 August 2017

1 reference

Marcello Arca

1

1 reference

17 August 2017

publication date

1 January 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

67 Suppl 1

1 reference

17 August 2017

page(s)

43-54

1 reference

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

17 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767001-00005

Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial

21 January 2018

1 reference

12 December 2020

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

1 reference

12 December 2020

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

1 reference

12 December 2020

The future of best practice

1 reference

12 December 2020

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

1 reference

12 December 2020

Standards of medical care in diabetes

1 reference

12 December 2020

Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study

1 reference

12 December 2020

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

1 reference

12 December 2020

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

1 reference

12 December 2020

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

12 December 2020

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

1 reference

12 December 2020

Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials

1 reference

12 December 2020

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

12 December 2020

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

1 reference

12 December 2020

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

1 reference

12 December 2020

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

12 December 2020

Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary

1 reference

12 December 2020

Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)

1 reference

12 December 2020

Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial.

1 reference

12 December 2020

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

12 December 2020

Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus

1 reference

12 December 2020

10.2165/00003495-200767001-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

17 August 2017

1033401433

0 references

1 reference